A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAS7660
U.S. Govt. ID: NCT03460977
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to learn about the effects of the study drug PF 06821497, and to find the best dose for treating small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), and follicular lymphoma (FL). This study will help researchers learn about the safety of PF-06821497 and how it is absorbed, distributed, broken down, and removed from the body.This research study will be the first time PF-06821497 will be given to people. The dose of PF-06821497 to be used to treat patients is unknown. During Part 1A of this research study, different doses of PF-06821497 were tested in patients with advanced tumors (SCLC CRPC, diffuse large B-cell lymphoma DLBCL, and FL) to determine the starting dose levels for Parts 1B and 2A.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Do you have a diagnosis of SCLC, CRPC, or FL? Yes No
Are you 18 years of age or older? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162